164 related articles for article (PubMed ID: 30994873)
1. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.
Cardones AR; Sullivan KM; Green C; Chao NJ; Rowe-Nichols K; Bañez LL; Burton CS; Horwitz ME; Long GD; Rao CL; Sarantopoulos S; Sidhu-Malik N; Sung AD; Hall RP
JAMA Dermatol; 2019 Jul; 155(7):833-837. PubMed ID: 30994873
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
3. Interrater reproducibility of the Myoton and durometer devices to quantify sclerotic chronic graft-versus-host disease.
Ghosh S; Baker L; Chen F; Khera Z; Vain A; Zhang K; Hood A; Smith H; Chen H; Jagasia M; Tkaczyk E
Arch Dermatol Res; 2023 Nov; 315(9):2545-2554. PubMed ID: 37227518
[TBL] [Abstract][Full Text] [Related]
4. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
Mitchell SA; Jacobsohn D; Thormann Powers KE; Carpenter PA; Flowers ME; Cowen EW; Schubert M; Turner ML; Lee SJ; Martin P; Bishop MR; Baird K; Bolaños-Meade J; Boyd K; Fall-Dickson JM; Gerber LH; Guadagnini JP; Imanguli M; Krumlauf MC; Lawley L; Li L; Reeve BB; Clayton JA; Vogelsang GB; Pavletic SZ
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1619-29. PubMed ID: 21536143
[TBL] [Abstract][Full Text] [Related]
5. Genetic risk factors for sclerotic graft-versus-host disease.
Inamoto Y; Martin PJ; Flowers ME; Lee SJ; Carpenter PA; Warren EH; Geraghty DE; Lee N; Boeckh MJ; Storer BE; Levine DM; Fan W; Zhao LP; Hansen JA
Blood; 2016 Sep; 128(11):1516-24. PubMed ID: 27313329
[TBL] [Abstract][Full Text] [Related]
6. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease.
Baumrin E; Shin DB; Mitra N; Pidala J; El Jurdi N; Lee SJ; Loren AW; Gelfand JM
JAMA Dermatol; 2024 Apr; 160(4):393-401. PubMed ID: 38416506
[TBL] [Abstract][Full Text] [Related]
8. Oral chronic graft-versus-host disease scoring using the NIH consensus criteria.
Treister NS; Stevenson K; Kim H; Woo SB; Soiffer R; Cutler C
Biol Blood Marrow Transplant; 2010 Jan; 16(1):108-14. PubMed ID: 19772943
[TBL] [Abstract][Full Text] [Related]
9. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
[TBL] [Abstract][Full Text] [Related]
10. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
11. A single-center pilot validation study of a new chronic GVHD skin scoring system.
Greinix HT; Pohlreich D; Maalouf J; Soukup P; Supper V; Kalhs P; Knobler RM
Biol Blood Marrow Transplant; 2007 Jun; 13(6):715-23. PubMed ID: 17531782
[TBL] [Abstract][Full Text] [Related]
12. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease.
Clark J; Yao L; Pavletic SZ; Krumlauf M; Mitchell S; Turner ML; Cowen EW
Arch Dermatol; 2009 Aug; 145(8):918-22. PubMed ID: 19687424
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.
Pidala J; Kurland B; Chai X; Majhail N; Weisdorf DJ; Pavletic S; Cutler C; Jacobsohn D; Palmer J; Arai S; Jagasia M; Lee SJ
Blood; 2011 Apr; 117(17):4651-7. PubMed ID: 21355084
[TBL] [Abstract][Full Text] [Related]
15. Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.
Shakshouk H; Tkaczyk ER; Cowen EW; El-Azhary RA; Hashmi SK; Kenderian SJ; Lehman JS
Transplant Cell Ther; 2021 Sep; 27(9):738-746. PubMed ID: 34107339
[TBL] [Abstract][Full Text] [Related]
16. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
17. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
18. Chronic cutaneous graft-versus-host disease in children: A report of 14 patients from a tertiary care pediatric dermatology clinic.
Nanda A; Husain MAA; Al-Herz W; Almekaimi A; Al-Sabah H; Al-Otaibi M
Pediatr Dermatol; 2018 May; 35(3):343-353. PubMed ID: 29536565
[TBL] [Abstract][Full Text] [Related]
19. Evolving concepts in prognostic scoring of chronic GvHD.
Lazaryan A; Arora M
Bone Marrow Transplant; 2017 Oct; 52(10):1361-1366. PubMed ID: 28346419
[TBL] [Abstract][Full Text] [Related]
20. The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.
Tecchio C; Mosna F; Andreini A; Paoli L; Di Bella R; de Sabata D; Sorio M; Pizzolo G; Benedetti F
Leuk Lymphoma; 2013 May; 54(5):1020-7. PubMed ID: 23035648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
